JP2001514013A - Ｌｔｃ４シンターゼ多型の分析方法および診断への利用 - Google Patents
Ｌｔｃ４シンターゼ多型の分析方法および診断への利用Info
- Publication number
- JP2001514013A JP2001514013A JP2000507836A JP2000507836A JP2001514013A JP 2001514013 A JP2001514013 A JP 2001514013A JP 2000507836 A JP2000507836 A JP 2000507836A JP 2000507836 A JP2000507836 A JP 2000507836A JP 2001514013 A JP2001514013 A JP 2001514013A
- Authority
- JP
- Japan
- Prior art keywords
- ltc
- polymorphism
- synthase gene
- synthase
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000003745 diagnosis Methods 0.000 title claims abstract description 5
- 102100023758 Leukotriene C4 synthase Human genes 0.000 title 1
- 108010087711 leukotriene-C4 synthase Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 239000002773 nucleotide Substances 0.000 claims abstract description 38
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 38
- 150000002617 leukotrienes Chemical class 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 108700028369 Alleles Proteins 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 19
- 150000007523 nucleic acids Chemical group 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 230000002590 anti-leukotriene effect Effects 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 4
- 239000002751 oligonucleotide probe Substances 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 abstract description 11
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 4
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000013615 primer Substances 0.000 description 39
- 230000035772 mutation Effects 0.000 description 33
- 239000012634 fragment Substances 0.000 description 18
- 238000001514 detection method Methods 0.000 description 14
- 102000054765 polymorphisms of proteins Human genes 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 13
- 238000002405 diagnostic procedure Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 208000009657 Aspirin-Induced Asthma Diseases 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000037429 base substitution Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 description 3
- 229960004764 zafirlukast Drugs 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 101100436100 Caenorhabditis elegans asp-6 gene Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 101100514359 Mus musculus Mrtfa gene Proteins 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9717766.1A GB9717766D0 (en) | 1997-08-22 | 1997-08-22 | Methods |
| GB9717766.1 | 1997-08-22 | ||
| PCT/GB1998/002468 WO1999010529A1 (en) | 1997-08-22 | 1998-08-18 | Methods for analyzing ltc4 synthase polymorphisms and diagnostic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001514013A true JP2001514013A (ja) | 2001-09-11 |
| JP2001514013A5 JP2001514013A5 (enExample) | 2006-01-05 |
Family
ID=10817852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000507836A Pending JP2001514013A (ja) | 1997-08-22 | 1998-08-18 | Ｌｔｃ４シンターゼ多型の分析方法および診断への利用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6316196B1 (enExample) |
| EP (1) | EP1007738A1 (enExample) |
| JP (1) | JP2001514013A (enExample) |
| AU (1) | AU8814798A (enExample) |
| GB (2) | GB9717766D0 (enExample) |
| WO (1) | WO1999010529A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881571B1 (en) | 1998-03-11 | 2005-04-19 | Exonhit Therapeutics S.A. | Qualitative differential screening |
| FR2798392B1 (fr) * | 1999-09-13 | 2005-07-15 | Exonhit Therapeutics Sa | Marqueurs genetiques de la toxicite, preparation et utilisations |
| AU3793701A (en) * | 1999-11-29 | 2001-06-04 | Orchid Biosciences, Inc. | Methods of identifying optimal drug combinations and compositions thereof |
| WO2001079560A2 (en) * | 2000-04-17 | 2001-10-25 | Glaxo Group Limited | Medicine response assay in respiratory disease |
| CN1329012A (zh) * | 2000-06-21 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——烟酰胺腺嘌呤脱氧二核苷酸依赖性白三烯b412－羟基脱氢酶36和编码这种多肽的多核甘酸 |
| US20050009023A1 (en) * | 2001-07-03 | 2005-01-13 | Neil Richtand | Glucocorticoid-induced receptor and methods of use |
| CA2458303A1 (en) * | 2001-09-17 | 2003-03-27 | Janssen Pharmaceutica N.V. | Brain expressed cap-2 gene and protein associated with bipolar disorder |
| US7833706B2 (en) * | 2003-01-30 | 2010-11-16 | Celera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
| US20050019795A1 (en) * | 2003-04-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders |
| EP2186913B1 (en) * | 2003-11-26 | 2016-02-10 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| US20090297563A1 (en) * | 2004-10-27 | 2009-12-03 | Anders Borglum | Diagnosis And Treatment of Immune-Related Diseases |
| WO2007059348A2 (en) * | 2005-11-17 | 2007-05-24 | Third Wave Technologies, Inc. | Compositions and methods for detecting an hcv-1 subtype |
| EP2027284A2 (en) * | 2006-05-18 | 2009-02-25 | Sanofi-Aventis | Use of adamts4 gene and protein polymorphisms |
| CA2653794C (en) * | 2006-06-30 | 2012-05-01 | Clifford L. Librach | Method of detecting preeclampsia |
| WO2008033239A2 (en) * | 2006-09-11 | 2008-03-20 | Applera | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof |
| WO2008039941A2 (en) | 2006-09-27 | 2008-04-03 | The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services | Scgb3a2 as a growth factor and anti-apoptotic agent |
| US7811765B2 (en) * | 2006-10-12 | 2010-10-12 | Children's Hospital & Research Center At Oakland | Methods and compositions for determining predisposition to inflammation-mediated cardiovascular disease |
| US20080248470A1 (en) * | 2007-04-04 | 2008-10-09 | Sungkyunkwan University Foundation For Corporate Collaboration | Genetic screening for predicting antidepressant drug response based on the monoamine transporter gene polymorphism combination |
| US9079961B2 (en) * | 2007-05-25 | 2015-07-14 | Japanese Red Cross Society | GPIIIa gene |
| WO2009052160A1 (en) * | 2007-10-19 | 2009-04-23 | Marshfield Clinic | Method for administering anticoagulation therapy |
| WO2009061734A1 (en) * | 2007-11-05 | 2009-05-14 | The Government Of The United States Of America As Represented By The Secretary Of The Deparment Of Health And Human Services | Identification of subjects likely to benefit from statin therapy |
| US7947451B2 (en) * | 2007-11-30 | 2011-05-24 | Celera Corporation | Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof |
| US10023913B2 (en) * | 2008-01-29 | 2018-07-17 | The Johns Hopkins University | SR-BI as a predictor of elevated high density lipoprotein and cardiovascular disease |
| US20110112186A1 (en) * | 2008-02-29 | 2011-05-12 | Isis Innovation Limited | Diagnostic methods |
| US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
| US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
| DE102008064509B4 (de) * | 2008-12-22 | 2017-06-08 | Robert Bosch Gesellschaft mbH für medizinische Forschung | Verfahren zur Bestimmung der Prädisposition für Morbus Crohn |
| CA2706021C (en) * | 2009-05-28 | 2018-10-16 | Institut De Cardiologie De Montreal | Genetic predictors of international normalized ratio (inr) fluctuation with warfarin therapy |
| WO2011068610A1 (en) * | 2009-12-01 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Methods for detecting risk of myelodysplastic syndrome by genotypic analysis |
| US9732389B2 (en) | 2010-09-03 | 2017-08-15 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| WO2012082912A2 (en) * | 2010-12-14 | 2012-06-21 | Tufts Medical Center, Inc. | Markers related to age-related macular degeneration and uses therefor |
| US9534256B2 (en) * | 2011-01-06 | 2017-01-03 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer |
| AU2012322018B2 (en) | 2011-10-13 | 2017-09-21 | Boston Heart Diagnostics | Compositions and methods for treating and preventing coronary heart disease |
| US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
| US10098893B2 (en) * | 2013-10-03 | 2018-10-16 | Northwestern University | Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457 |
| EP3149487B1 (en) * | 2014-05-29 | 2020-02-12 | Geneticure LLC | Improved therapeutic regimen for hypertension |
| US11761043B2 (en) | 2014-05-29 | 2023-09-19 | Geneticure Inc. | Machine assay and analysis for selecting antihypertensive drugs |
| US10260108B2 (en) * | 2014-11-04 | 2019-04-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | PARP genomic variants conferring resistance and sensitization to chemotherapy under inhibition |
| CA2968221A1 (en) | 2014-11-17 | 2016-05-26 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993018178A1 (en) * | 1992-03-13 | 1993-09-16 | The Children's Hospital Of Philadelphia | DIAGNOSIS OF β-THALASSEMIA USING A MULTIPLEX AMPLIFICATION REFRACTORY MUTATION SYSTEM |
| CA2136239C (en) | 1992-06-15 | 2004-10-05 | Donald W. Nicholson | Leukotriene c4 synthase |
| WO1995032280A1 (en) * | 1994-05-20 | 1995-11-30 | Brigham And Women's Hospital | Dna encoding human leukotriene c4 synthase, polypeptides, and uses therefor |
| US5952210A (en) * | 1994-06-03 | 1999-09-14 | G. D. Searle & Company | Nucleic acids and expression vectors encoding human leukotiene C4 synthase |
| AU2927797A (en) | 1996-05-06 | 1997-11-26 | Brigham And Women's Hospital | 5-lipoxygenase gene polymorphisms and their use in classifying patients |
-
1997
- 1997-08-22 GB GBGB9717766.1A patent/GB9717766D0/en active Pending
-
1998
- 1998-08-18 EP EP98939738A patent/EP1007738A1/en not_active Withdrawn
- 1998-08-18 GB GB0001527A patent/GB2342717B/en not_active Expired - Fee Related
- 1998-08-18 US US09/485,636 patent/US6316196B1/en not_active Expired - Fee Related
- 1998-08-18 JP JP2000507836A patent/JP2001514013A/ja active Pending
- 1998-08-18 WO PCT/GB1998/002468 patent/WO1999010529A1/en not_active Ceased
- 1998-08-18 AU AU88147/98A patent/AU8814798A/en not_active Abandoned
-
2001
- 2001-10-31 US US09/984,842 patent/US20030077592A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030077592A1 (en) | 2003-04-24 |
| EP1007738A1 (en) | 2000-06-14 |
| GB2342717A (en) | 2000-04-19 |
| AU8814798A (en) | 1999-03-16 |
| WO1999010529A1 (en) | 1999-03-04 |
| GB9717766D0 (en) | 1997-10-29 |
| US6316196B1 (en) | 2001-11-13 |
| GB0001527D0 (en) | 2000-03-15 |
| GB2342717B (en) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001514013A (ja) | Ｌｔｃ４シンターゼ多型の分析方法および診断への利用 | |
| ES2252159T3 (es) | Polimorfismos en el gen humano del transportador de anion organico c (oatp-c). | |
| EP1130123A2 (en) | Diagnostic method | |
| JP2002272482A (ja) | ハプロタイプ決定のためのｐｃｒに基づく多重アッセイ | |
| WO2000079003A1 (en) | Polymorphisms in the human hmg-coa reductase gene | |
| US20030032099A1 (en) | Methods for predicting susceptibility to obesity and obesity-associated health problems | |
| JP2003530844A (ja) | 呼吸器疾患における医薬応答アッセイ | |
| JP2002521063A (ja) | ヒトｃｃｒ−２遺伝子多型性 | |
| EP1100962A1 (en) | Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases | |
| JP2001522586A (ja) | 慢性閉塞性気道疾患に対する診断法および治療法 | |
| US20020160362A1 (en) | Diagnostic method | |
| US20030157484A1 (en) | Chemical compounds | |
| WO2000017392A1 (en) | Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases | |
| EP1184465A2 (en) | Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms | |
| JP2002521061A (ja) | ヒトのニューロキニン２受容体遺伝子における遺伝多型、並びに疾患の診断および処置におけるそれらの使用 | |
| JP2002526090A (ja) | インテグリンリガンド仲介疾患の診断および処置に適当なヒトのベータ１インテグリンサブユニット遺伝子における多型性 | |
| JP2002533135A (ja) | ヒトにおけるピルビン酸デヒドロゲナーゼキナーゼイソ酵素２（ｐｄｋ２）の一塩基多型 | |
| US20040132024A1 (en) | Method of detecting genetic disorders | |
| US20050118579A1 (en) | Chemical compounds | |
| JP2002531144A (ja) | 第ｘ因子および／または第ｘａ因子仲介疾患の診断および処置における第ｘ因子多型性の使用 | |
| US20060147953A1 (en) | Methods of diagnosing cardiovascular disease | |
| WO2006073183A1 (ja) | 一塩基多型を用いた炎症性疾患の判定方法 | |
| JPWO2006068111A1 (ja) | ＰＰＡＲγ遺伝子の遺伝子多型に関連する表現型の判定方法 | |
| MXPA00004381A (en) | Diagnostics and therapeutics for chronic obstructive airway disease | |
| JPWO2004078963A1 (ja) | ステロイド応答性の検査方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050803 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081105 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090406 |